George Seed

6.6k total citations
21 papers, 422 citations indexed

About

George Seed is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, George Seed has authored 21 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Cancer Research and 7 papers in Oncology. Recurrent topics in George Seed's work include Prostate Cancer Treatment and Research (16 papers), Cancer Genomics and Diagnostics (9 papers) and Cancer, Lipids, and Metabolism (4 papers). George Seed is often cited by papers focused on Prostate Cancer Treatment and Research (16 papers), Cancer Genomics and Diagnostics (9 papers) and Cancer, Lipids, and Metabolism (4 papers). George Seed collaborates with scholars based in United Kingdom, United States and France. George Seed's co-authors include Johann S. de Bono, Diletta Bianchini, Joaquı́n Mateo, David Olmos, Susana Miranda, Mateus Crespo, Howard I. Scher, David Lorente, Leon W.M.M. Terstappen and David Dolling and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

George Seed

18 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
George Seed United Kingdom 8 289 241 206 112 32 21 422
Rachel Schaefer United States 8 299 1.0× 137 0.6× 88 0.4× 115 1.0× 33 1.0× 14 382
Yang Peng China 13 123 0.4× 204 0.8× 206 1.0× 228 2.0× 16 0.5× 44 485
André Mansinho Portugal 11 109 0.4× 101 0.4× 220 1.1× 149 1.3× 50 1.6× 36 400
Annamaria Siggillino Italy 13 324 1.1× 138 0.6× 256 1.2× 274 2.4× 15 0.5× 24 514
Xiangli Jiang China 14 171 0.6× 222 0.9× 171 0.8× 307 2.7× 11 0.3× 23 512
Grigorios Chlouverakis Greece 5 256 0.9× 395 1.6× 566 2.7× 113 1.0× 26 0.8× 6 659
Kaikai Zhao China 10 173 0.6× 146 0.6× 108 0.5× 222 2.0× 14 0.4× 27 420
Ines Figueiredo United Kingdom 11 356 1.2× 232 1.0× 237 1.2× 185 1.7× 93 2.9× 26 576
Anton Safonov United States 7 134 0.5× 135 0.6× 321 1.6× 127 1.1× 48 1.5× 36 451
Ruth Riisnaes United Kingdom 5 299 1.0× 231 1.0× 201 1.0× 90 0.8× 57 1.8× 5 431

Countries citing papers authored by George Seed

Since Specialization
Citations

This map shows the geographic impact of George Seed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Seed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Seed more than expected).

Fields of papers citing papers by George Seed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George Seed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Seed. The network helps show where George Seed may publish in the future.

Co-authorship network of co-authors of George Seed

This figure shows the co-authorship network connecting the top 25 collaborators of George Seed. A scholar is included among the top collaborators of George Seed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Seed. George Seed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Seed, George, Semini Sumanasuriya, Cláudia Bertan, et al.. (2020). Abstract LB-270: Discovery of genomic correlates and tumor purity as an independent clinical factor of poor outcome in advanced prostate cancer lpWGS CNA data. Cancer Research. 80(16_Supplement). LB–270. 1 indexed citations
5.
Sumanasuriya, Semini, George Seed, Niven Mehra, et al.. (2019). Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.. Journal of Clinical Oncology. 37(15_suppl). 5070–5070. 2 indexed citations
6.
Paschalis, Alec, Beshara Sheehan, Ruth Riisnaes, et al.. (2019). PSMA heterogeneity and DNA repair defects in prostate cancer.. Journal of Clinical Oncology. 37(15_suppl). 5002–5002. 1 indexed citations
7.
Mateo, Joaquı́n, Núria Porta, Ursula McGovern, et al.. (2019). TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.. Journal of Clinical Oncology. 37(15_suppl). 5005–5005. 36 indexed citations
8.
Mehra, Niven, David Dolling, Semini Sumanasuriya, et al.. (2018). Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). European Urology. 74(3). 283–291. 78 indexed citations
9.
Lorente, David, David Olmos, Joaquı́n Mateo, et al.. (2018). Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Annals of Oncology. 29(7). 1554–1560. 72 indexed citations
10.
Mateo, Joaquı́n, Suzanne Carreira, George Seed, et al.. (2018). Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 36(15_suppl). 5013–5013. 4 indexed citations
11.
Rescigno, Pasquale, Gunther Boysen, Daniel Nava Rodrigues, et al.. (2018). Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.. Journal of Clinical Oncology. 36(15_suppl). 5064–5064. 1 indexed citations
12.
Rescigno, Pasquale, Mattia Rediti, David Dolling, et al.. (2018). PI3K/AKT pathway deleterious mutations in lethal prostate cancer. Annals of Oncology. 29. viii293–viii293. 3 indexed citations
13.
Lorente, David, David Olmos, Joaquı́n Mateo, et al.. (2016). Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European Urology. 70(6). 985–992. 113 indexed citations
14.
Mehra, Niven, George Seed, Maryou Lambros, et al.. (2016). Myeloid-derived suppressor cells (MDSCs) in metastatic castration-resistant prostate cancer (CRPC) patients (PTS). Annals of Oncology. 27. vi257–vi257. 6 indexed citations
15.
Rodrigues, Daniel Nava, Gunther Boysen, Semini Sumanasuriya, et al.. (2016). The molecular underpinnings of prostate cancer: impacts on management and pathology practice. The Journal of Pathology. 241(2). 173–182. 29 indexed citations
16.
Lorente, David, David Olmos, Joaquı́n Mateo, et al.. (2015). Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.. Journal of Clinical Oncology. 33(15_suppl). 5014–5014. 4 indexed citations
17.
Ong, Michael, Suzanne Carreira, Jane Goodall, et al.. (2014). Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. British Journal of Cancer. 111(5). 828–836. 23 indexed citations
18.
Pezaro, Carmel, Deborah Mukherji, Nina Tunariu, et al.. (2013). Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. British Journal of Cancer. 109(2). 325–331. 36 indexed citations
19.
Seed, George, et al.. (1956). The treatment of cancer of the larynx. Journal of the Faculty of Radiologists. 8(2). 92–101. 1 indexed citations
20.
Seed, George. (1951). Malignant tumours of the upper jaw. Journal of the Faculty of Radiologists. 2(4). 263–271.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachel Schaefer Breakdown of academic impact, for papers by Yang Peng Breakdown of academic impact, for papers by André Mansinho Breakdown of academic impact, for papers by Annamaria Siggillino Breakdown of academic impact, for papers by Xiangli Jiang Breakdown of academic impact, for papers by Grigorios Chlouverakis Breakdown of academic impact, for papers by Kaikai Zhao Breakdown of academic impact, for papers by Ines Figueiredo Breakdown of academic impact, for papers by Anton Safonov Breakdown of academic impact, for papers by Ruth Riisnaes
Rankless by CCL
2026